Estrogen-related cancer microenvironment of breast carcinoma

Endocrine Journal

Volumn 56, Issue 1, 2009, Pages 1-7

  Yamaguchi, Yuri ^a   Hayashi, Shin Ichi ^b  

^a SAITAMA CANCER CENTER   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aromatase; Breast cancer; Estrogen signal; Stromal fibroblast

Indexed keywords

AROMATASE; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CXCL1 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; STROMAL CELL DERIVED FACTOR 1;

ANGIOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER INVASION; CELL INTERACTION; CELL PROLIFERATION; ESTROGEN SYNTHESIS; FIBROBLAST; HUMAN; METASTASIS; MICROENVIRONMENT; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL;

BREAST NEOPLASMS; CARCINOMA; ENVIRONMENT; ESTROGENS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 62549090621     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K08E-099     Document Type: Review

References (33)

1. Shao ZM, Nguyen M, Barsky SH (2000) Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19: 4337-4345.
2. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nature Rev Cancer 6: 392-401.
3. Orimo A, Weinberg, RA (2006) Stromal fibroblasts in Cancer. Cell Cycle 5: 1597-1601.
4. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti- Domenici J, Huang AH, Porter D, Hu aM, Chinh L, Richardson A, Schniff S, Seller WR, Polyak K (2004) Molecular characterization of the tumor microenviron- ment in breast cancer. Cancer Cell 6: 17-32.
5. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/ CXCL12 secretion. Cell 121: 335-348.
6. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, Sahai E (2007) Fibroblast- led collective invasion of carcinoma cells with differing roles for RhoGTPase in leading and following cells. Nature Cell Biol 9: 1392-1400.
7. O'Neill JS, Miller WR (1987) Aromatase activity in breast adipose tissue from women with benign and malignant breast disease. Br J Cancer 56: 601-604.
8. Santen RJ, Santner SJ, Pauley RJ, Tait L, Kaseta J, Demers LM, Hamilton C, Yue W, Wang JP (1997) Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J Steroid Biochem Mol Biol 61: 267-271.
9. Osborne CK, Shou J, Massarweh S, Schiff R (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistancein breast cancer. Clin Cancer Res 11: 865s- 870s.
10. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS (1994) Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269: 4458-4466.
11. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494.
12. Hayashi S, Yamaguchi Y (2005) Estrogen signaling and prediction of endocrine therapy. Cancer Chemother. Pharmacol., 56: 27-31.
13. Norman AW, Mizwicki MT, Norman DP (2004) Steroid- hormone rapid actions, membrane receptors and a conformational ensemble model. Nature Reviews 3: 27-41.
14. Levin ER (2005) Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19: 1951- 1959.
15. Bjornstrom L, Sjoberg, M (2005) Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19: 833-842.
16. Yamaguchi Y (2007) Microenvironmental regulation of estrogen signals in breast cancer. Breast Cancer 14: 175-181.
17. Simpson ER, Davis SR (2001) Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 142: 4589-4594.
18. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists' Group. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139.
19. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane Study (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081-1092.
20. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793- 1802.
21. Coates AS, Keshaviah A, Thtirlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione- Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25: 486-492.
22. Kato S, Masuhiro Y, Watanabe M, Kobayashi Y, Takeyama K, Endoh H, Yanagisawa J (2005) Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells 5: 593-601.
23. Bunone G, Briand P-A, Miksicek RJ, Picard D (1996) Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation, EMBO J. 15: 2174-2183.
24. Arnold SF, Obourn JD, Jaffe H, Notides AC (1994) Ser 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol 8: 1208-1214.
25. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA (1998) pp90srkl regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 18: 1978-1984.
26. Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CK (1994) Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ 5: 1275-1282.
27. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T (1994) Estrogen regulation of the insulinlike growth factor I gene transcription involves an AP- 1 enhancer. J Biol Chem 269: 16433-16442.
28. Yamaguchi Y, Takei H, Suemasu K, Kobayashi Y, Kurosumi F, Harada N, Hayashi S-I (2005) Tumor- stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Res 65: 4653- 4662.
29. Luker KE, Luker GD (2006) Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett238: 30-41.
30. Hall JM, Korach KS (2003) Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 17: 792-803.
31. Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, Pumiglia K, Gallick GE, Price JE (2005) CXCL12/stromal cell-derived factor-la transactivates HER2-neu in breast cancer ells by a novel pathway involving Src kinase activation. Cancer Res 65: 6493- 6497.
32. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC (2004) Upregulation of CXCR4 is essential for HER2- mediated tumor metastasis. Cancer Cell 6: 459-469.
33. Matteucci E, Locati M, Desiderio MA (2005) Hepato- cyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness. Exp Cell Res 310: 176-185.